- Home
- LPCN vs EQS Comparison
LPCN vs EQS Comparison
Compare LPCN & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- EQS
- Stock Information
- Founded
- LPCN 1997
- EQS 1991
- Country
- LPCN United States
- EQS United States
- Employees
- LPCN N/A
- EQS N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- EQS Finance Companies
- Sector
- LPCN Health Care
- EQS Finance
- Exchange
- LPCN Nasdaq
- EQS Nasdaq
- Market Cap
- LPCN 16.1M
- EQS 13.9M
- IPO Year
- LPCN N/A
- EQS N/A
- Fundamental
- Price
- LPCN $3.16
- EQS $0.85
- Analyst Decision
- LPCN Strong Buy
- EQS
- Analyst Count
- LPCN 1
- EQS 0
- Target Price
- LPCN $10.00
- EQS N/A
- AVG Volume (30 Days)
- LPCN 22.1K
- EQS 5.3K
- Earning Date
- LPCN 05-08-2025
- EQS 01-01-0001
- Dividend Yield
- LPCN N/A
- EQS N/A
- EPS Growth
- LPCN N/A
- EQS N/A
- EPS
- LPCN N/A
- EQS N/A
- Revenue
- LPCN $3,674,834.00
- EQS $1,274,000.00
- Revenue This Year
- LPCN N/A
- EQS N/A
- Revenue Next Year
- LPCN N/A
- EQS N/A
- P/E Ratio
- LPCN N/A
- EQS N/A
- Revenue Growth
- LPCN N/A
- EQS 411.65
- 52 Week Low
- LPCN $2.75
- EQS $0.87
- 52 Week High
- LPCN $11.79
- EQS $1.53
- Technical
- Relative Strength Index (RSI)
- LPCN 48.60
- EQS 37.57
- Support Level
- LPCN $2.68
- EQS $0.74
- Resistance Level
- LPCN $3.46
- EQS $1.01
- Average True Range (ATR)
- LPCN 0.33
- EQS 0.05
- MACD
- LPCN -0.02
- EQS -0.01
- Stochastic Oscillator
- LPCN 51.97
- EQS 33.94
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.